Prior To 3Q Earnings, J.P. Morgan Rates The Best In Biotechnology

On the cusp of the 3Q10 earnings season for biotechnology, J.P. Morgan is providing an overview of the companies within the industry. This quarter, Acorda Therapeutics, Inc. ACOR and Celgene Corporation CELG are the leaders of the pack. “We are modestly raising our Revlimid forecast to $605M from $598M previously (cons: $601M),” J.P. Morgan writes, speaking about Celgene. “We believe Revlimid could have another solid quarter provided share and duration gains as well as favorable OUS trends continue.” Celgene currently trades for $57.95; Acorda trades for $29.24.